Thomas Demarini
Pulmonary Disease · Decatur, GANPI 1407831696
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,220 of the $59,191 with a category attached, or 81.5%. GSK accounts for 76.5% of it on its own, with 46 other manufacturers making up the rest. Reporting peaked in 2022 at $37,427 and has fallen 99.9% since, to $25 in 2025. Among pulmonary disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 594 payments — averaging $99.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$45K
- Boehringer Ingelheim$7K
- AstraZeneca$1K
- Harmony Biosciences LLC$620
- Actelion Pharmaceuticals US, Inc.$559
- Jazz Pharmaceuticals Inc.$539
- plus $4K from 41 others
Across 1 payment — averaging $70.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$70
What the payments were for
- Speaking & faculty fees$48,22081%
- Travel & lodging$7381%
- Food & beverage$9,79317%
- Education$4401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$29,745
How this compares
$59,191 in reported general payments places this provider in the 95th percentile of 365 pulmonary disease providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 11 | $131,234 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $58,083 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $884 |
| Famotidine | 33 | $454 |
| Gabapentin | 17 | $201 |
| Omeprazole | 21 | $157 |
| Azithromycin | 16 | $99 |
| Prednisone | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $559 | $131,23411 claims |
| GSKTrelegy Ellipta | $45,264 | $58,08361 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Decatur
- David MillerDecatur$206K
- Jose AristizabalDecatur$18K
- Chuansheng WuDecatur$17K
- Harold JacksonDecatur$15K
- Lawrence McDermottSavannah$963K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.